Restenosis, the achilles' heel of coronary angioplasty

Richard L. Wurdeman, Daniel E. Hilleman, Aryan N. Mooss

Research output: Contribution to journalReview article

14 Citations (Scopus)

Abstract

Coronary angioplasty is widely performed for the management of symptomatic coronary artery disease. With improvements in technique, operator experience, and tools, more complex lesions are being treated. Unfortunately, luminal renarrowing continues to limit the long-term success of the procedure, resulting in the need for repeat revascularization in approximately 30% of patients within 6 months. As the pathophysiologic process of restenosis is better defined, various pharmacologic and mechanical interventions have been tried to attenuate the process. Some agents are antithrombotics, antiplatelets, angiotensin-converting enzyme inhibitors, lipid-lowering drugs, and calcium channel blockers. Improvement has been noted with the newer glycoprotein IIb- and IIIa-blocking agents, mechanical stents, and radioactive materials. Whether these new compounds will withstand the test of time is unknown.

Original languageEnglish
Pages (from-to)1024-1040
Number of pages17
JournalPharmacotherapy
Volume18
Issue number5
StatePublished - Sep 1998

Fingerprint

Platelet Glycoprotein GPIIb-IIIa Complex
Fibrinolytic Agents
Platelet Aggregation Inhibitors
Calcium Channel Blockers
Angioplasty
Angiotensin-Converting Enzyme Inhibitors
Stents
Coronary Artery Disease
Lipids
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Restenosis, the achilles' heel of coronary angioplasty. / Wurdeman, Richard L.; Hilleman, Daniel E.; Mooss, Aryan N.

In: Pharmacotherapy, Vol. 18, No. 5, 09.1998, p. 1024-1040.

Research output: Contribution to journalReview article

@article{b68ac45371324e72b3c333afba21a704,
title = "Restenosis, the achilles' heel of coronary angioplasty",
abstract = "Coronary angioplasty is widely performed for the management of symptomatic coronary artery disease. With improvements in technique, operator experience, and tools, more complex lesions are being treated. Unfortunately, luminal renarrowing continues to limit the long-term success of the procedure, resulting in the need for repeat revascularization in approximately 30{\%} of patients within 6 months. As the pathophysiologic process of restenosis is better defined, various pharmacologic and mechanical interventions have been tried to attenuate the process. Some agents are antithrombotics, antiplatelets, angiotensin-converting enzyme inhibitors, lipid-lowering drugs, and calcium channel blockers. Improvement has been noted with the newer glycoprotein IIb- and IIIa-blocking agents, mechanical stents, and radioactive materials. Whether these new compounds will withstand the test of time is unknown.",
author = "Wurdeman, {Richard L.} and Hilleman, {Daniel E.} and Mooss, {Aryan N.}",
year = "1998",
month = "9",
language = "English",
volume = "18",
pages = "1024--1040",
journal = "Pharmacotherapy",
issn = "0277-0008",
publisher = "Pharmacotherapy Publications Inc.",
number = "5",

}

TY - JOUR

T1 - Restenosis, the achilles' heel of coronary angioplasty

AU - Wurdeman, Richard L.

AU - Hilleman, Daniel E.

AU - Mooss, Aryan N.

PY - 1998/9

Y1 - 1998/9

N2 - Coronary angioplasty is widely performed for the management of symptomatic coronary artery disease. With improvements in technique, operator experience, and tools, more complex lesions are being treated. Unfortunately, luminal renarrowing continues to limit the long-term success of the procedure, resulting in the need for repeat revascularization in approximately 30% of patients within 6 months. As the pathophysiologic process of restenosis is better defined, various pharmacologic and mechanical interventions have been tried to attenuate the process. Some agents are antithrombotics, antiplatelets, angiotensin-converting enzyme inhibitors, lipid-lowering drugs, and calcium channel blockers. Improvement has been noted with the newer glycoprotein IIb- and IIIa-blocking agents, mechanical stents, and radioactive materials. Whether these new compounds will withstand the test of time is unknown.

AB - Coronary angioplasty is widely performed for the management of symptomatic coronary artery disease. With improvements in technique, operator experience, and tools, more complex lesions are being treated. Unfortunately, luminal renarrowing continues to limit the long-term success of the procedure, resulting in the need for repeat revascularization in approximately 30% of patients within 6 months. As the pathophysiologic process of restenosis is better defined, various pharmacologic and mechanical interventions have been tried to attenuate the process. Some agents are antithrombotics, antiplatelets, angiotensin-converting enzyme inhibitors, lipid-lowering drugs, and calcium channel blockers. Improvement has been noted with the newer glycoprotein IIb- and IIIa-blocking agents, mechanical stents, and radioactive materials. Whether these new compounds will withstand the test of time is unknown.

UR - http://www.scopus.com/inward/record.url?scp=0031711397&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031711397&partnerID=8YFLogxK

M3 - Review article

C2 - 9758313

AN - SCOPUS:0031711397

VL - 18

SP - 1024

EP - 1040

JO - Pharmacotherapy

JF - Pharmacotherapy

SN - 0277-0008

IS - 5

ER -